title: Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increases chemosensitivity to cisplatin in laryngeal carcinoma Hep2 cells.
abstract: CD147, also named extracelluar matrix metalloproteinase inducer (EMMPRIN), is a member of the immunoglobulin family and a glycoprotein enriched on the surface of tumor cells, which promotes invasion, metastasis, growth and survival of malignant cells, and is known to confer resistance to some chemotherapeutic drugs. To determine the possible role of CD147 in the invasive properties of laryngeal carcinoma, we used an RNA interference approach to silence CD147 expression in the Hep2 cell line at high levels of CD147 expression. Our results showed that CD147 expression was significantly impeded at both mRNA and protein levels, which resulted in a decrease of the Hep2 invasion activity in vitro and tumorigenicity in nude mice. The suppression of CD147 expression also sensitized cells to cisplatin. Our current results indicated that CD147 was a laryngeal carcinoma-related gene and CD147 might be a potential target for therapeutic anti-cancer drugs.
authors.affiliation: Department of Life Sciences, Nanjing Normal University, and Central Laboratory, Nanjing First Hospital, Nanjing, Jiangsu 210046, PR China.
authors.forename: Chan
authors.initials: C
authors.lastname: Zhu
authors.forename: Yuqin
authors.initials: Y
authors.lastname: Pan
authors.forename: Bangshun
authors.initials: B
authors.lastname: He
authors.forename: Bo
authors.initials: B
authors.lastname: Wang
authors.forename: Yongfei
authors.initials: Y
authors.lastname: Xu
authors.forename: Lili
authors.initials: L
authors.lastname: Qu
authors.forename: Qian
authors.initials: Q
authors.lastname: Bao
authors.forename: Fuliang
authors.initials: F
authors.lastname: Tian
authors.forename: Shukui
authors.initials: S
authors.lastname: Wang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D051926:Basigin / Q000235:genetics*; D002277:Carcinoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D018450:Disease Progression; D015536:Down-Regulation / Q000187:drug effects; D019008:Drug Resistance, Neoplasm / Q000187:drug effects* / Q000235:genetics; D004357:Drug Synergism; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D055785:Gene Knockdown Techniques; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009361:Neoplasm Invasiveness; D034622:RNA Interference / Q000502:physiology; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000494:pharmacology*; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D034741:RNA, Small Interfering; D051926:Basigin; D002945:Cisplatin